Upconversion Nanoparticles Y2O3 and Gd2O3 Co-Doped with Er3+ and Yb3+ with Aminosilane-Folic Acid Functionalization for Breast and Cervix Cancer Cells Detection

被引:1
作者
D. Chávez-García
K. Juárez-Moreno
G. A. Hirata
机构
[1] Carretera Ensenada-Tijuana 3918 Zona Playitas,Centro de Investigación Científica y de Educación Superior de Ensenada
[2] Ensenada,Centro de Nanociencias y Nanotecnología
[3] Universidad Nacional Autónoma de México,undefined
关键词
D O I
10.1557/adv.2017.447
中图分类号
学科分类号
摘要
The upconversion nanoparticles (UCNPs) possess the ability to absorb near infrared energy (980 nm) and upconvert it to emit in the visible spectra. In this research, the UNCPs emit in red (660 nm) due to the electronic transitions between two rare earth ions: Er3+ and Yb3+, this process is called energy transfer upconversion (ETU). The UCNPs were functionalized with aminosilanes and folic acid receptors (UCNP-FR) and analyzed by transmission electron microscopy, Fourier transform infrared spectroscopy and luminescence measurements. UCNPs-FR of Y2O3 have a particle size of 70 ± 10 nm and the Gd2O3 have a 50 ± 10 nm particle size. Both showed a good luminescence spectrum in comparison with the bare ones. Cytotoxicity of different amounts between 0.001 μg/ml to 1 μg/ml of bare and functionalized UCNPs was measured with the colorimetric assay MTT in three cancer cell lines: human cervical adenocarcinoma (HeLa), human breast cancer cells MB-MDA-231. Some concentrations of bare UCNPs were cytotoxic for cancer cells; however after their functionalization they resulted to be non-cytotoxic. The functionalized UCNPs were able to bind to folate receptors which are overexpressed in cervical and breast cancers cells. It was demonstrated by confocal microscopy, that the functionalized UCNPs were internalized into the cancer cells, confirming that they can be used as biolabels for breast and cervical cancer cells.
引用
收藏
页码:2983 / 2988
页数:5
相关论文
共 46 条
  • [1] Min L(2012)undefined Biotechnology Advances 30 1551-1561
  • [2] Ying Z(2011)undefined Nanomedicine: Nanotechnology, Biology, and Medicine 7 710-729
  • [3] ShuQi W(2009)undefined J. Alloys Compds 469 224-228
  • [4] Ming Liu(2016)undefined Nanotechnol 6 7-17
  • [5] Duan Z(2000)undefined Adv. Drug Deliv. Rev 41 147-162
  • [6] Chen Y(2004)undefined Adv. Drug Deliv. Rev 56 1161-1176
  • [7] Li Y(1968)undefined J. Colloid Interface Sci 26 62-69
  • [8] Xu F(2009)undefined Proceedings 23 1741-1744
  • [9] Lu T(2009)undefined Biomaterials 30 5592-5600
  • [10] Wang M(2013)undefined Yamano, Kishimoto, Venkatachalam, Hyodo, Soga, Acta Biomater 9 4734-4743